deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT00486512

Chemoprevention of Colorectal Adenomas

A Clinical Trial Evaluating the Efficacy and Safety of a Combination Treatment Administered Over 3 Years in Patients at Risk of Experiencing Recurrence of Colorectal Adenomas

Sponsor: Colotech A/S

Updated 10 times since 2017 Last updated: Aug 31, 2020 Started: Jun 30, 2007 Primary completion: Nov 30, 2010 Completion: Nov 30, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The overall program was terminated

Listed as NCT00486512, this PHASE3 trial focuses on Adenomatous Polyps and remains terminated or withdrawn. Sponsored by Colotech A/S, it has been updated 10 times since 2007, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Study Description(click to expand)

This is a multicenter, randomized, parallel group, prospective, double blind, placebo controlled clinical trial of chemoprevention in patients at increased risk of developing colorectal cancer (CRC). The Colotech combination treatment (acetylsalicylic acid, 1α 25-dihydroxy cholecalciferol, and calcium carbonate) will be compared to placebo with regards to safety and efficacy during 3 years of treatment. The randomized treatment period will be preceded by a 3-week single blind placebo run-in period, which will assess patient's compliance to treatment. In order to collect data on the durability of treatment effect, follow-up data from a surveillance colonoscopy will be collected two years after the 3-year colonoscopy.

This is a multicenter, randomized, parallel group, prospective, double blind, placebo controlled clinical trial of chemoprevention in patients at increased risk of developing colorectal cancer (CRC). The Colotech combination treatment (acetylsalicylic acid, 1α 25-dihydroxy cholecalciferol, and calcium carbonate) will be compared to placebo with regards to safety and efficacy during 3 years of treatment. The randomized treatment period will be preceded by a 3-week single blind placebo run-in period, which will assess patient's compliance to treatment. In order to collect data on the durability of treatment effect, follow-up data from a surveillance colonoscopy will be collected two years after the 3-year colonoscopy.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshotTerminated~Mar 2019 – ~Oct 2020 · 19 months · monthly snapshotTerminated~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshotTerminated~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotTerminated~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 7 months · monthly snapshotTerminated

Change History

10 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Apr 2022 — Jul 2024 [monthly]

    Terminated PHASE3

  5. Jan 2021 — Apr 2022 [monthly]

    Terminated PHASE3

Show 5 earlier versions
  1. Oct 2020 — Jan 2021 [monthly]

    Terminated PHASE3

  2. Mar 2019 — Oct 2020 [monthly]

    Terminated PHASE3

  3. Jun 2018 — Mar 2019 [monthly]

    Terminated PHASE3

  4. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE3

  5. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE3

    First recorded

Jun 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Colotech A/S
Data source: Colotech A/S

For direct contact, visit the study record on ClinicalTrials.gov .